Youngchul Kim
0000-0002-2307-0330
3 papers found
Refreshing results…
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer
WNT5A–RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer
Missing publications? Search for publications with a matching author name.